Donovski L
Khirurgiia (Sofiia). 1989;42(4):28-30.
Twenty five patients with chronic urogenital infections (cystitis, pyelitis and prostatitis) were treated with Solco urovak infection which is active against Escherichia coli, Proteus, Klebsiella and Streptococcus fecalis organisms. This microbial flora has been isolated from these patients and proved resistant to the conventional antibacterial agents. The vaccine was very well tolerated, gave no side reactions, but transient short lasting rise of the temperature to 38 degrees C. The bacteriologic control on the 6. week after vaccination showed sterile urine in 68 per cent of the patients, no change in 20 per cent and recovery of other bacterial flora in 12 per cent. The vaccine is recommended for treatment of urinary tract infections caused by the microorganisms enumerated above.
25名患有慢性泌尿生殖系统感染(膀胱炎、肾盂炎和前列腺炎)的患者接受了索尔科尿活疫苗(Solco urovak)治疗,该疫苗对大肠杆菌、变形杆菌、克雷伯菌和粪链球菌具有活性。这些微生物菌群已从这些患者中分离出来,并被证明对传统抗菌药物耐药。该疫苗耐受性良好,未出现副作用,但有短暂的体温升高至38摄氏度的情况。接种疫苗6周后的细菌学检查显示,68%的患者尿液无菌,20%的患者情况无变化,12%的患者出现其他细菌菌群恢复。推荐使用该疫苗治疗由上述微生物引起的尿路感染。